A Phase II Trial of Brivanib in Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

PURPOSE: Brivanib, an oral, multi-targeted tyrosine kinase inhibitor with activity against vascular endothelial growth factor (VEGF) and fibroblast growth factor receptor (FGFR) was investigated as a single agent in a phase II trial to assess the activity and tolerability in recurrent or persistent...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Gynecol Oncol
Päätekijät: Powell, Matthew A., Sill, Michael W., Goodfellow, Paul J., Benbrook, Doris M., Lankes, Heather A., Leslie, Kimberly K., Jeske, Yvette, Mannel, Robert S., Spillman, Monique A, Lee, Paula S., Hoffman, James S., McMeekin, D. Scott, Pollock, Pamela M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2014
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4278402/
https://ncbi.nlm.nih.gov/pubmed/25019571
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2014.07.083
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia